Table 1 Characteristics of included studies
From: The efficacy of pregabalin for pain control after thoracic surgery: a meta-analysis
- | Author | Pregabalin group | Control group | Jada scores | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | Age (years) | Male (n) | Smoking (n) | Methods | Number | Age (years) | Male (n) | Smoking (n) | Methods | |||
1 | Homma 2019 | 46 | 67, median | 33 | 31 | pregabalin (25 mg, twice daily) | 46 | 70, median | 28 | 25 | non-steroidal anti-inflammatory drugs | 3 |
2 | Gaber 2019 | 30 | 46.9 ± 10.1 | 22 | - | pregabalin 150 mg every 12 h | 30 | 41.0 ± 14.5 | 21 | - | placebo | 4 |
3 | Kim 2017 | 30 | 56 ± 12 | 13 | - | pregabalin 150 mg 1 h before anesthesia | 30 | 58 ± 9 | 17 | - | placebo | 5 |
4 | Miyazaki 2016 | 33 | 66, median | 15 | - | pregabalin (75 mg, twice daily) | 34 | 69, median | 22 | - | nothing | 3 |
5 | Yoshimura 2015 | 25 | 69.2 ± 9.0 | 12 | - | pregabalin (75 mg, twice daily) | 25 | 65.2 ± 10.4 | 12 | - | nothing | 3 |